Published in Neurology on September 13, 2007
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
Fingolimod after natalizumab and the risk of short-term relapse. Neurology (2014) 1.96
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology (2009) 1.73
De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol (2011) 1.35
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol (2011) 1.10
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS One (2012) 0.93
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol (2012) 0.88
Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag (2009) 0.86
Multiple sclerosis imaging: recent advances. J Neurol (2012) 0.85
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? Ther Clin Risk Manag (2013) 0.85
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities. Mult Scler Int (2015) 0.85
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol (2013) 0.83
Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord (2010) 0.82
Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurol Sci (2013) 0.81
Is natalizumab overshooting its rebound? Neurology (2008) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol (2014) 0.81
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. J Neurol (2013) 0.80
From injection therapies to natalizumab: views on the treatment of multiple sclerosis. Ther Adv Neurol Disord (2012) 0.80
Monoclonal antibodies as disease modifying therapy in multiple sclerosis. Curr Neurol Neurosci Rep (2013) 0.79
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. Neurol Sci (2011) 0.78
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. Neurol Ther (2015) 0.78
Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm (2016) 0.78
Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions. BMC Neurol (2014) 0.77
Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs (2014) 0.77
Update. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2008) 0.75
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav (2017) 0.75
Multiple sclerosis: Is there a safe time to discontinue therapy in MS? Nat Rev Neurol (2016) 0.75
Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. Clinicoecon Outcomes Res (2009) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex (2007) 5.28
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
Cervical lymph node metastasis: assessment of radiologic criteria. Radiology (1990) 3.24
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci (1993) 3.16
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: how reliable is it? AJNR Am J Neuroradiol (1998) 2.48
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature (1995) 2.44
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology (2012) 2.25
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology (2011) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology (2010) 2.03
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]. Ned Tijdschr Geneeskd (2004) 2.03
Regional DTI differences in multiple sclerosis patients. Neuroimage (2008) 2.03
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler (2006) 1.99
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol (2001) 1.94
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging (2006) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology (2009) 1.88
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology (2010) 1.88
Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol (1995) 1.87
Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology (1995) 1.86
Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain (2008) 1.84
CT and MRI rating of white matter lesions. Cerebrovasc Dis (2002) 1.83
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke (2003) 1.78
Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett (2000) 1.77
White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain (1992) 1.77
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
MR venography of multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.72
Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev (2005) 1.69
Hippocampal atrophy in Alzheimer disease: age matters. Neurology (2006) 1.66
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia (2006) 1.66
Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci (2011) 1.66
Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol (2010) 1.66
Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology (2004) 1.65
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology (1995) 1.63
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology (2008) 1.62
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol (2009) 1.60
Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology (1998) 1.58
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain (2001) 1.56
Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. Hippocampus (2000) 1.55
Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol (2001) 1.54
Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.53
Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet (1995) 1.53
Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis. Ann Neurol (2001) 1.53